|1.||Mathews, Maju: 8 articles (11/2015 - 01/2014)|
|2.||Edwards, John: 7 articles (07/2015 - 03/2013)|
|3.||Nunez, Rene: 6 articles (11/2015 - 11/2014)|
|4.||Gommoll, Carl: 5 articles (11/2015 - 11/2014)|
|5.||Chen, Dalei: 5 articles (07/2015 - 02/2014)|
|6.||Gallipoli, Susan: 5 articles (10/2013 - 04/2011)|
|7.||Reed, Carol R: 5 articles (10/2013 - 03/2009)|
|8.||Boinpally, Ramesh: 4 articles (07/2015 - 03/2013)|
|9.||Thase, Michael E: 4 articles (06/2015 - 01/2012)|
|10.||Masand, Prakash S: 4 articles (04/2015 - 07/2013)|
|1.||Major Depressive Disorder (Major Depressive Disorders)
02/01/2014 - "Early and sustained improvement with vilazodone in adult patients with major depressive disorder: post hoc analyses of two phase III trials."
11/01/2014 - "Vilazodone may be effective in treating patients with major depressive disorder who exhibit somatic and/or psychic symptoms of anxiety. "
01/01/2014 - "To assess clinically relevant symptom improvement in patients with major depressive disorder (MDD) receiving vilazodone by using the Montgomery-Asberg Depression Rating Scale (MADRS), a clinician-rated scale used to measure MDD symptom severity and improvement. "
04/01/2012 - "Vilazodone for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?"
01/01/2012 - "As a new option for the treatment of major depressive disorder, vilazodone, due to its unique SPARI mechanism of action, may hold promise for patients who cannot tolerate or have not responded to previous antidepressant monotherapies. "
01/01/2014 - "A significantly greater proportion of vilazodone-treated versus placebo-treated patients shifted from baseline ≥ 4 to end of study ≤ 2 on MADRS items of apparent sadness, reported sadness, inner tension, reduced sleep, and lassitude (OR range, 1.5-2.0, P < .05). "
06/01/2015 - "Nausea, diarrhea, dizziness, vomiting, and fatigue were reported in ≥5% of patients in either vilazodone group and at least twice the rate of placebo. "
04/01/2012 - "Vilazodone appears to have a favourable weight-gain profile based on short-term studies. "
08/01/2013 - "Certain pharmacological characteristics of vilazodone were observed, including early onset of action, fewer sexual side effects, the absence of known cardiac toxicity, and minimal effect on weight gain, that may provide potential clinical advantages compared with currently available antidepressants. "
01/01/2012 - "Although no head-to-head studies against other antidepressants are published, the efficacy data for vilazodone appears comparable to other known antidepressants, with associated gastrointestinal side effects similar to serotonin selective reuptake inhibitor and serotonin norepinephrine reuptake inhibitor antidepressants, but potentially with a lower incidence of sexual side effects and weight gain. "
06/01/2011 - "Although no head-to-head studies against other antidepressants have been published, the efficacy data for vilazodone appear comparable to other known antidepressants, with similar gastrointestinal side effects to SSRI or serotonin norepinephrine reuptake inhibitor (SNRI) antidepressants, but possibly with a lower incidence of sexual side effects and weight gain. "
|4.||Anxiety Disorders (Anxiety Disorder)
11/01/2015 - "Vilazodone in patients with generalized anxiety disorder: a double-blind, randomized, placebo-controlled, flexible-dose study."
06/01/2015 - "This study (NCT01629966 ClinicalTrials.gov) evaluated the efficacy and safety of vilazodone in adults with generalized anxiety disorder (GAD). "
06/01/2015 - "A double-blind, randomized, placebo-controlled, fixed-dose phase III study of vilazodone in patients with generalized anxiety disorder."
11/01/2015 - "The efficacy, safety, and tolerability of vilazodone for generalized anxiety disorder (GAD) were investigated in a clinical trial (NCT01766401 ClinicalTrials.gov). "
01/01/2015 - "Vilazodone, which has been described as the first-of-class SPARI medication, may potentially have benefits for subgroups of patients, particularly those depressed individuals with coexisting anxiety symptoms or anxiety disorders. "
07/01/2011 - "Vilazodone was generally well tolerated in the short- and long-term treatment of MDD, with diarrhoea and nausea being the most frequently occurring treatment-emergent adverse events. "
01/01/2015 - "Most common adverse events, including diarrhea and nausea, were evaluated, and safety assessments indicated that vilazodone was well tolerated (diarrhea odds ratio 3.54, 95% confidence interval 2.81-4.45; P<0.00001; nausea odds ratio 3.85, 95% confidence interval 3.00-4.96; P<0.00001; discontinuations due to adverse events odds ratio 2.71, 95% confidence interval 1.81-4.05; P<0.00001). "
11/01/2014 - "Patients taking vilazodone versus placebo had higher rates of diarrhea and nausea; most incidences were mild in severity. "
10/01/2012 - "Vilazodone was generally well tolerated, with nausea and diarrhea being the most frequent adverse events reported. "
03/01/2009 - "Treatment-emergent adverse events with vilazodone included diarrhea, nausea, and somnolence; most adverse events were of mild or moderate intensity. "
|2.||Serotonin (5 Hydroxytryptamine)
|3.||Antidepressive Agents (Antidepressants)
|5.||5-HT1A Serotonin Receptor
|6.||S 20098 (agomelatine)
|8.||Serotonin Uptake Inhibitors (Serotonin Reuptake Inhibitors)
|9.||Serotonin Receptor Agonists (Serotonin Receptor Agonist)